Percutaneous Dilatational Tracheostomy: Ultra-perc Versus Ciaglia Blue Dolphin
Launched by MOHAMED SAYED MOHAMED ABBAS · Apr 27, 2016
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
The investigators conducted a prospective randomized trial to compare Ultra-perc single stage dilator technique (UP) and Ciaglia Blue Dolphin ballon dilatation technique (CBD) From January 2013 to December 2015.
The investigators compared the two groups as regards Procedure difficulties including difficult dilatation, difficult tube insertion, failed tube insertion, false passage and tracheal stoma over dilatation. and Procedure complications including cardiac arrest, pneumothorax, pneumomediastinum, subcutaneous emphysema, hemorrhage and lung atelectasis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • sepsis
- • cerebrovascular accidents
- • cervical cord injury
- • traumatic brain injury
- • post arrest and chronic obstructive pulmonary disease
- Exclusion Criteria:
- • patient or family refusal
- • emergency tracheostomy
- • distorted abnormal anatomy
- • bleeding diathesis
- • morbid obesity
- • previous tracheostomy
- • infected surgical site
- • Adult respiratory distress syndrome patients requiring high positive end expiratory pressure and high oxygen demands
About Mohamed Sayed Mohamed Abbas
Mohamed Sayed Mohamed Abbas is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the pharmaceutical and healthcare sectors, he focuses on the development and execution of innovative clinical trials that adhere to the highest standards of regulatory compliance and ethical practices. His leadership is characterized by a collaborative approach, fostering partnerships with healthcare professionals, research institutions, and regulatory bodies to ensure the successful translation of scientific discoveries into effective therapeutic solutions. Through his efforts, Mohamed Sayed Mohamed Abbas aims to contribute significantly to the evolution of modern medicine and the enhancement of public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials